

Paul F Mckay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/93702/publications.pdf>

Version: 2024-02-01

74
papers

2,774
citations

186265

28
h-index

206112

48
g-index

87
all docs

87
docs citations

87
times ranked

4062
citing authors

#	ARTICLE	IF	CITATIONS
1	Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. <i>Nature Communications</i> , 2020, 11, 3523.	12.8	357
2	Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. <i>Gene Therapy</i> , 2019, 26, 363-372.	4.5	137
3	Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 Vaccines. <i>Journal of Virology</i> , 2003, 77, 8729-8735.	3.4	120
4	Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. <i>Journal of Clinical Investigation</i> , 2004, 114, 1334-1342.	8.2	105
5	Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. <i>Nature Communications</i> , 2021, 12, 2893.	12.8	104
6	Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer. <i>ACS Nano</i> , 2020, 14, 5711-5727.	14.6	92
7	Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. <i>EClinicalMedicine</i> , 2022, 44, 101262.	7.1	87
8	Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations. <i>Journal of Controlled Release</i> , 2012, 162, 529-537.	9.9	80
9	Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. <i>European Journal of Immunology</i> , 2004, 34, 1011-1020.	2.9	69
10	Neutrophils Enable Local and Non-Invasive Liposome Delivery to Inflamed Skeletal Muscle and Ischemic Heart. <i>Advanced Materials</i> , 2020, 32, e2003598.	21.0	66
11	Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. <i>Journal of Clinical Investigation</i> , 2004, 114, 1334-1342.	8.2	62
12	Advances in HIV-1 Vaccine Development. <i>Viruses</i> , 2018, 10, 167.	3.3	56
13	Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines. <i>Journal of Controlled Release</i> , 2021, 338, 201-210.	9.9	53
14	One Size Does Not Fit All: The Effect of Chain Length and Charge Density of Poly(ethylene imine) Based Copolymers on Delivery of pDNA, mRNA, and RepRNA Polyplexes. <i>Biomacromolecules</i> , 2018, 19, 2870-2879.	5.4	51
15	Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers. <i>Cell Reports</i> , 2018, 24, 3324-3338.e5.	6.4	49
16	Elicitation of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Mucosal Compartments of Rhesus Monkeys by Systemic Vaccination. <i>Journal of Virology</i> , 2002, 76, 11484-11490.	3.4	47
17	Mutations that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway. <i>Cell Reports</i> , 2022, 38, 110344.	6.4	46
18	The Skin You Are In: Design-of-Experiments Optimization of Lipid Nanoparticle Self-Amplifying RNA Formulations in Human Skin Explants. <i>ACS Nano</i> , 2019, 13, 5920-5930.	14.6	44

#	ARTICLE	IF	CITATIONS
19	Innate Inhibiting Proteins Enhance Expression and Immunogenicity of Self-Amplifying RNA. <i>Molecular Therapy</i> , 2021, 29, 1174-1185.	8.2	40
20	Antibody responses after intravaginal immunisation with trimeric HIV-1CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. <i>Vaccine</i> , 2011, 29, 1421-1430.	3.8	39
21	Vaccine Protection Against Functional CTL Abnormalities in Simian Human Immunodeficiency Virus-Infected Rhesus Monkeys. <i>Journal of Immunology</i> , 2002, 168, 332-337.	0.8	38
22	Isolation and Characterization of Antigen-Specific Plasmablasts Using a Novel Flow Cytometry-Based Ig Capture Assay. <i>Journal of Immunology</i> , 2017, 199, 4180-4188.	0.8	37
23	Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection. <i>Journal of Controlled Release</i> , 2013, 170, 452-459.	9.9	36
24	Glucopyranosyl Lipid A Adjuvant Significantly Enhances HIV Specific T and B Cell Responses Elicited by a DNA-MVA-Protein Vaccine Regimen. <i>PLoS ONE</i> , 2014, 9, e84707.	2.5	36
25	A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes. <i>Frontiers in Immunology</i> , 2017, 8, 149.	4.8	35
26	Evidence of NK cell dysfunction in SIV-infected rhesus monkeys: Impairment of cytokine secretion and NKG2C/C2 expression. <i>European Journal of Immunology</i> , 2006, 36, 2424-2433.	2.9	34
27	Enhanced Immunogenicity of an HIV-1 DNA Vaccine Delivered with Electroporation via Combined Intramuscular and Intradermal Routes. <i>Journal of Virology</i> , 2014, 88, 6959-6969.	3.4	32
28	<i>Chlamydia trachomatis</i> : Cell biology, immunology and vaccination. <i>Vaccine</i> , 2021, 39, 2965-2975.	3.8	32
29	The gp200-MR6 molecule which is functionally associated with the IL-4 receptor modulates B cell phenotype and is a novel member of the human macrophage mannose receptor family. <i>European Journal of Immunology</i> , 1998, 28, 4071-4083.	2.9	31
30	Structural Components for Amplification of Positive and Negative Strand VEEV Spltzicons. <i>Frontiers in Molecular Biosciences</i> , 2018, 5, 71.	3.5	31
31	Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA. <i>Journal of Controlled Release</i> , 2019, 304, 65-74.	9.9	30
32	Mannosylated Poly(ethylene imine) Copolymers Enhance saRNA Uptake and Expression in Human Skin Explants. <i>Biomacromolecules</i> , 2020, 21, 2482-2492.	5.4	30
33	Effect of complexing lipids on cellular uptake and expression of messenger RNA in human skin explants. <i>Journal of Controlled Release</i> , 2021, 330, 1250-1261.	9.9	28
34	Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms. <i>Vaccine</i> , 2011, 29, 4512-4520.	3.8	27
35	TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes. <i>PLoS ONE</i> , 2016, 11, e0148984.	2.5	27
36	Global Dysfunction of CD4 T-Lymphocyte Cytokine Expression in Simian-Human Immunodeficiency Virus/SIV-Infected Monkeys Is Prevented by Vaccination. <i>Journal of Virology</i> , 2003, 77, 4695-4702.	3.4	26

#	ARTICLE	IF	CITATIONS
37	Identification of potential biomarkers of vaccine inflammation in mice. <i>ELife</i> , 2019, 8, .	6.0	25
38	A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances <i>Chlamydia trachomatis</i> Clearance. <i>Frontiers in Immunology</i> , 2016, 7, 162.	4.8	24
39	Mucosal Tissue Tropism and Dissemination of HIV-1 Subtype B Acute Envelope-Expressing Chimeric Virus. <i>Journal of Virology</i> , 2013, 87, 890-899.	3.4	23
40	Combined Influence of B-Cell Receptor Rearrangement and Somatic Hypermutation on B-Cell Class-Switch Fate in Health and in Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2018, 9, 1784.	4.8	22
41	Intramuscular Immunisation with Chlamydial Proteins Induces <i>Chlamydia trachomatis</i> Specific Ocular Antibodies. <i>PLoS ONE</i> , 2015, 10, e0141209.	2.5	20
42	A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. <i>Frontiers in Immunology</i> , 2017, 8, 595.	4.8	20
43	The <i>In Vitro</i> , <i>Ex Vivo</i> , and <i>In Vivo</i> Effect of Polymer Hydrophobicity on Charge-Reversible Vectors for Self-Amplifying RNA. <i>Biomacromolecules</i> , 2020, 21, 3242-3253.	5.4	20
44	Mucosal Application of gp140 Encoding DNA Polyplexes to Different Tissues Results in Altered Immunological Outcomes in Mice. <i>PLoS ONE</i> , 2013, 8, e67412.	2.5	19
45	Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses. <i>Journal of Controlled Release</i> , 2017, 249, 74-83.	9.9	18
46	Molecular Signatures of a TLR4 Agonist-Adjuvanted HIV-1 Vaccine Candidate in Humans. <i>Frontiers in Immunology</i> , 2018, 9, 301.	4.8	18
47	A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system. <i>Npj Vaccines</i> , 2018, 3, 2.	6.0	17
48	Discrete partitioning of HIV-1 Env forms revealed by viral capture. <i>Retrovirology</i> , 2015, 12, 81.	2.0	16
49	Evaluation of CD62L expression as a marker for vaccine-elicited memory cytotoxic T lymphocytes. <i>Immunology</i> , 2005, 116, 050920031238006.	4.4	15
50	A systematic analysis of the expression of the anti-HIV VRC01 antibody in <i>Pichia pastoris</i> through signal peptide optimization. <i>Protein Expression and Purification</i> , 2018, 149, 43-50.	1.3	15
51	Expressing anti-HIV VRC01 antibody using the murine IgG1 secretion signal in <i>Pichia pastoris</i> . <i>AMB Express</i> , 2017, 7, 70.	3.0	14
52	Presentation of antigen on extracellular vesicles using transmembrane domains from viral glycoproteins for enhanced immunogenicity. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12199.	12.2	14
53	Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination. <i>Frontiers in Immunology</i> , 2017, 8, 1883.	4.8	13
54	Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against COVID-19: COVAC1, a Phase I, Dose-Ranging Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	13

#	ARTICLE	IF	CITATIONS
55	Immunogenicity of stabilized HIV-1 Env trimers delivered by self-amplifying mRNA. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 25, 483-493.	5.1	13
56	A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection. <i>EBioMedicine</i> , 2020, 59, 102853.	6.1	12
57	Next-generation COVID-19 vaccines: here come the proteins. <i>Lancet, The</i> , 2021, 397, 643-645.	13.7	9
58	Flow Cytometric Analysis. <i>Methods in Molecular Medicine</i> , 2000, 40, 407-414.	0.8	8
59	Chemokine-Adjuvanted Plasmid DNA Induces Homing of Antigen-Specific and Non-“Antigen-Specific B and T Cells to the Intestinal and Genital Mucosae. <i>Journal of Immunology</i> , 2020, 204, 903-913.	0.8	8
60	Precisely targeted gene delivery in human skin using supramolecular cationic glycopolymers. <i>Polymer Chemistry</i> , 2020, 11, 3768-3774.	3.9	8
61	Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility. <i>Journal of Virological Methods</i> , 2022, 302, 114475.	2.1	8
62	Seasonal Betacoronavirus Antibodies™ Expansion Post-BNT161b2 Vaccination Associates with Reduced SARS-CoV-2 VoC Neutralization. <i>Journal of Clinical Immunology</i> , 2022, 42, 448-458.	3.8	7
63	A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model. <i>Vaccine</i> , 2022, 40, 2848-2855.	3.8	7
64	Optimisation of ex vivo memory B cell expansion/differentiation for interrogation of rare peripheral memory B cell subset responses. <i>Wellcome Open Research</i> , 0, 2, 97.	1.8	6
65	Optimisation of ex vivo memory B cell expansion/differentiation for interrogation of rare peripheral memory B cell subset responses. <i>Wellcome Open Research</i> , 2017, 2, 97.	1.8	6
66	Plasmid DNA Vaccine Co-Immunisation Modulates Cellular and Humoral Immune Responses Induced by Intranasal Inoculation in Mice. <i>PLoS ONE</i> , 2015, 10, e0141557.	2.5	6
67	Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency. <i>Frontiers in Immunology</i> , 2021, 12, 750386.	4.8	6
68	Molecular investigations into vaginal immunization with HIV gp41 antigenic construct H4A in a quick release solid dosage form. <i>Vaccine</i> , 2012, 30, 2778-2785.	3.8	5
69	CD71 targeting boosts immunogenicity of sublingually delivered influenza haemagglutinin antigen and protects against viral challenge in mice. <i>Journal of Controlled Release</i> , 2016, 232, 75-82.	9.9	4
70	Detection and Quantification of Antibody to SARS-CoV-2 Receptor Binding Domain Provides Enhanced Sensitivity, Specificity and Utility. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
71	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2022, 7, 44.	6.0	2
72	Isolating Pathogen-Specific Human Monoclonal Antibodies (hmAbs) Using Bacterial Whole Cells as Molecular Probes. <i>Methods in Molecular Biology</i> , 2021, 2183, 9-18.	0.9	1

#	ARTICLE	IF	CITATIONS
73	Combinations of TLR4 and TLR7/8 Adjuvants Administered via the ID or IN Routes Generate Different Vaccine Antigen-specific Immune Outcomes in Minipigs. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A194-A195.	1.1	0
74	Use of Chlamydial Elementary Bodies as Probes to Isolate Pathogen-Specific Human Monoclonal Antibodies. <i>Methods in Molecular Biology</i> , 2021, 2183, 19-28.	0.9	0